Arcutis Biotherapeutics (ARQT) Cash & Equivalents (2020 - 2025)
Arcutis Biotherapeutics has reported Cash & Equivalents over the past 6 years, most recently at $42.9 million for Q4 2025.
- Quarterly results put Cash & Equivalents at $42.9 million for Q4 2025, down 39.85% from a year ago — trailing twelve months through Dec 2025 was $42.9 million (down 39.85% YoY), and the annual figure for FY2025 was $42.9 million, down 39.85%.
- Cash & Equivalents for Q4 2025 was $42.9 million at Arcutis Biotherapeutics, down from $47.1 million in the prior quarter.
- Over the last five years, Cash & Equivalents for ARQT hit a ceiling of $288.7 million in Q1 2021 and a floor of $42.9 million in Q4 2025.
- Median Cash & Equivalents over the past 5 years was $81.5 million (2022), compared with a mean of $93.6 million.
- Biggest five-year swings in Cash & Equivalents: crashed 75.82% in 2022 and later soared 133.52% in 2024.
- Arcutis Biotherapeutics' Cash & Equivalents stood at $96.4 million in 2021, then plummeted by 44.38% to $53.6 million in 2022, then skyrocketed by 64.8% to $88.4 million in 2023, then dropped by 19.3% to $71.3 million in 2024, then tumbled by 39.85% to $42.9 million in 2025.
- The last three reported values for Cash & Equivalents were $42.9 million (Q4 2025), $47.1 million (Q3 2025), and $72.7 million (Q2 2025) per Business Quant data.